Preservation of Tetherin and CD4 Counter-Activities in Circulating Alleles despite Extensive Sequence Variation within HIV-1 Infected Individuals

English version České info

The HIV-1 Vpu protein is expressed from a bi-cistronic message late in the viral life cycle. It functions during viral assembly to maximise infectious virus release by targeting CD4 for proteosomal degradation and counteracting the antiviral protein tetherin (BST2/CD317). Single genome analysis of vpu repertoires throughout infection in 14 individuals infected with HIV-1 clade B revealed extensive amino acid diversity of the Vpu protein. For the most part, this variation in Vpu increases over the course of infection and is associated with predicted epitopes of the individual's MHC class I haplotype, suggesting CD8+ T cell pressure is the major driver of Vpu sequence diversity within the host. Despite this variability, the Vpu functions of targeting CD4 and counteracting both physical virus restriction and NF-κB activation by tetherin are rigorously maintained throughout HIV-1 infection. Only a minority of circulating alleles bear lesions in either of these activities at any given time, suggesting functional Vpu mutants are heavily selected against even at later stages of infection. Comparison of Vpu proteins defective for one or several functions reveals novel determinants of CD4 downregulation, counteraction of tetherin restriction, and inhibition of NF-κB signalling. These data affirm the importance of Vpu functions for in vivo persistence of HIV-1 within infected individuals, not simply for transmission, and highlight its potential as a target for antiviral therapy.

Vyšlo v časopise: Preservation of Tetherin and CD4 Counter-Activities in Circulating Alleles despite Extensive Sequence Variation within HIV-1 Infected Individuals. PLoS Pathog 10(1): e32767. doi:10.1371/journal.ppat.1003895
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003895

Souhrn

Zdroje

1. MalimMH, EmermanM (2008) HIV-1 accessory proteins–ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388–398.

2. LiY, NdjangoJB, LearnGH, RamirezMA, KeeleBF, et al. (2012) Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir. J Virol 86: 10776–10791.

3. SauterD, SchindlerM, SpechtA, LandfordWN, MunchJ, et al. (2009) Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6: 409–421.

4. DubeM, BegoMG, PaquayC, CohenEA (2010) Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 7: 114.

5. Le TortorecA, WilleyS, NeilSJ (2011) Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses 3: 520–540.

6. CockaLJ, BatesP (2012) Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog 8: e1002931.

7. GalaoRP, Le TortorecA, PickeringS, KueckT, NeilSJ (2012) Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe 12: 633–644.

8. TokarevA, SuarezM, KwanW, FitzpatrickK, SinghR, et al. (2013) Stimulation of NF-kappaB Activity by the HIV Restriction Factor BST2. J Virol 87: 2046–2057.

9. ShahAH, SowrirajanB, DavisZB, WardJP, CampbellEM, et al. (2010) Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 8: 397–409.

10. MatusaliG, PotestaM, SantoniA, CerboniC, DoriaM (2012) The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J Virol 86: 4496–4504.

11. MollM, AnderssonSK, Smed-SorensenA, SandbergJK (2010) Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood 116: 1876–1884.

12. AlterG, HeckermanD, SchneidewindA, FaddaL, KadieCM, et al. (2011) HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476: 96–100.

13. SauterD, UnterwegerD, VoglM, UsmaniSM, HeigeleA, et al. (2012) Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog 8: e1003093.

14. ViganR, NeilSJ (2011) Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol 85: 9737–9748.

15. SauterD, HueS, PetitSJ, PlantierJC, TowersGJ, et al. (2011) HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology 8: 103.

16. YangSJ, LopezLA, ExlineCM, HaworthKG, CannonPM (2011) Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 8: 78.

17. YangSJ, LopezLA, HauserH, ExlineCM, HaworthKG, et al. (2010) Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7: 13.

18. JiaB, Serra-MorenoR, NeidermyerW, RahmbergA, MackeyJ, et al. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5: e1000429.

19. ZhangF, WilsonSJ, LandfordWC, VirgenB, GregoryD, et al. (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6: 54–67.

20. Le TortorecA, NeilSJ (2009) Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 83: 11966–11978.

21. DouglasJL, BaiY, GustinJK, MosesAV (2013) A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress. Virology 441: 182–196.

22. VermaS, RonsardL, KapoorR, BanerjeaAC (2013) Genetic characterization of natural variants of Vpu from HIV-1 infected individuals from Northern India and their impact on virus release and cell death. PLoS One 8: e59283.

23. LiberatoreRA, BieniaszPD (2011) Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A 108: 18097–18101.

24. BarrettBS, SmithDS, LiSX, GuoK, HasenkrugKJ, et al. (2012) A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog 8: e1002596.

25. JonesPH, MehtaHV, MaricM, RollerRJ, OkeomaCM (2012) Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology 9: 10.

26. CasartelliN, SourisseauM, FeldmannJ, Guivel-BenhassineF, MalletA, et al. (2010) Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6: e1000955.

27. JollyC, BoothNJ, NeilSJ (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84: 12185–12199.

28. ZhongP, AgostoLM, IlinskayaA, DorjbalB, TruongR, et al. (2013) Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS One 8: e53138.

29. StrebelK, KlimkaitT, MaldarelliF, MartinMA (1989) Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 63: 3784–3791.

30. HomannS, SmithD, LittleS, RichmanD, GuatelliJ (2011) Upregulation of BST-2/Tetherin by HIV infection in vivo. J Virol 85: 10659–10668.

31. PillaiSK, Abdel-MohsenM, GuatelliJ, SkaskoM, MontoA, et al. (2012) Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 109: 3035–3040.

32. MikhailM, WangB, SaksenaNK (2003) Mechanisms involved in non-progressive HIV disease. AIDS Rev 5: 230–244.

33. AnzalaOA, NagelkerkeNJ, BwayoJJ, HoltonD, MosesS, et al. (1995) Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 171: 686–689.

34. PoropatichK, SullivanDJJr (2011) Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol 92: 247–268.

35. KeeleBF, GiorgiEE, Salazar-GonzalezJF, DeckerJM, PhamKT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552–7557.

36. ViganR, NeilSJ (2010) Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 84: 12958–12970.

37. KueckT, NeilSJ (2012) A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog 8: e1002609.

38. MagadanJG, BonifacinoJS (2012) Transmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu. J Virol 86: 757–772.

39. MargottinF, BourSP, DurandH, SeligL, BenichouS, et al. (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1: 565–574.

40. Van DammeN, GoffD, KatsuraC, JorgensonRL, MitchellR, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3: 245–252.

41. McNattMW, ZangT, BieniaszPD (2013) Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog 9: e1003299.

42. BourS, PerrinC, AkariH, StrebelK (2001) The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem 276: 15920–15928.

43. Besnard-GuerinC, BelaidouniN, LassotI, SegeralE, JobartA, et al. (2004) HIV-1 Vpu sequesters beta-transducin repeat-containing protein (betaTrCP) in the cytoplasm and provokes the accumulation of beta-catenin and other SCFbetaTrCP substrates. J Biol Chem 279: 788–795.

44. AlizonS, FraserC (2013) Within-host and between-host evolutionary rates across the HIV-1 genome. Retrovirology 10: 49.

45. Serra-MorenoR, JiaB, BreedM, AlvarezX, EvansDT (2011) Compensatory Changes in the Cytoplasmic Tail of gp41 Confer Resistance to Tetherin/BST-2 in a Pathogenic Nef-Deleted SIV. Cell Host Microbe 9: 46–57.

46. GotzN, SauterD, UsmaniSM, FritzJV, GoffinetC, et al. (2012) Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 12: 373–380.

47. LoschkoJ, SchlitzerA, DudziakD, DrexlerI, SandholzerN, et al. (2011) Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity. J Immunol 186: 6718–6725.

48. HotterD, KirchhoffF, SauterD (2013) HIV-1 Vpu does not degrade interferon regulatory factor 3. J Virol 87: 7160–7165.

49. Karin MS, L.M., editor (2010) NF-kappaB: A Network Hub Controlling Immunity, Inflammation, and Cancer: CSH Press.

50. LucasTM, JanakaSK, StephensEB, JohnsonMC (2012) Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail. PLoS One 7: e51741.

51. SchmidtS, FritzJV, BitzegeioJ, FacklerOT, KepplerOT (2011) HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio 2: e00036–00011.

52. MauxionF, Le BorgneR, Munier-LehmannH, HoflackB (1996) A casein kinase II phosphorylation site in the cytoplasmic domain of the cation-dependent mannose 6-phosphate receptor determines the high affinity interaction of the AP-1 Golgi assembly proteins with membranes. J Biol Chem 271: 2171–2178.

53. HillMS, RuizA, SchmittK, StephensEB (2010) Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression. Virology 397: 104–112.

54. SinghSK, MockelL, Thiagarajan-RosenkranzP, WittlichM, WillboldD, et al. (2012) Mapping the interaction between the cytoplasmic domains of HIV-1 viral protein U and human CD4 with NMR spectroscopy. FEBS J 279: 3705–3714.

55. TiganosE, YaoXJ, FriborgJ, DanielN, CohenEA (1997) Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule. J Virol 71: 4452–4460.

56. SchubertU, StrebelK (1994) Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol 68: 2260–2271.

57. SatoK, MisawaN, FukuharaM, IwamiS, AnDS, et al. (2012) Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol 86: 5000–5013.

58. DaveVP, HajjarF, DiengMM, HaddadE, CohenEA (2013) Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. Retrovirology 10: 128.

59. HatziioannouT, EvansDT (2012) Animal models for HIV/AIDS research. Nat Rev Microbiol 10: 852–867.

60. PalmerS, KearneyM, MaldarelliF, HalvasEK, BixbyCJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406–413.

61. Rambaut A (2002) Se-Al, version 2.0a11. Available: http://treebioedacuk/software/seal/ Accessed August 2013.

62. SilvestroD, MichalackI (2012) raxmlGUI: a graphical front-end for RAxML. Organisms Diversity & Evolution 12: 335–337.

63. Rambaut A (2006) Figtree, version 1.3.1. Available: http://treebioedacuk/software/figtree/ Accessed August 2013.

64. PondSL, FrostSD, MuseSV (2005) HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676–679.

65. DelportW, PoonAF, FrostSD, Kosakovsky PondSL (2010) Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics 26: 2455–2457.

66. NguyenKL, llanoM, AkariH, MiyagiE, PoeschlaEM, et al. (2004) Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319: 163–175.

67. MiyagiE, AndrewAJ, KaoS, StrebelK (2009) Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A 106: 2868–2873.

68. NiranjanakumariS, LasdaE, BrazasR, Garcia-BlancoMA (2002) Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods 26: 182–190.